论文部分内容阅读
目的观察罗格列酮对糖耐量异常患者的治疗效果。方法比较119例糖耐量异常患者在饮食加运动控制的基础上口服罗格列酮和安慰剂干预治疗,经治疗1年后,检测空腹血糖(FPG)及葡萄糖耐量试验(OGTT)后2 h血糖(2hPG),总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白(HDL)、胰岛素抵抗指数、空腹胰岛素(FINS)和OGTT后2 h胰岛素(PINS)水平的变化。结果罗格列酮组和安慰剂组治疗前糖耐量比较差异无统计学意义(P>0.05)。罗格列酮组与安慰剂组相比FPG、2HPG、TC、TG、LDL、FINS、PINS及糖尿病发病率均明显下降,HDL-C升高。结论罗格列酮能够降低糖耐量异常(IGT)人群糖尿病的发病率,在调节血脂、减轻胰岛素抵抗的同时,可使糖耐量异常明显改善。
Objective To observe the effect of rosiglitazone on patients with impaired glucose tolerance. Methods One hundred and nineteen patients with impaired glucose tolerance were treated with oral rosiglitazone and placebo on the basis of diet and exercise control. After one year of treatment, fasting blood glucose (FPG) and blood glucose 2 h after glucose tolerance test (OGTT) (2hPG), total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein (HDL), insulin resistance index, fasting insulin (FINS) and OGTT Changes in insulin (PINS) levels. Results There was no significant difference in glucose tolerance between rosiglitazone group and placebo group before treatment (P> 0.05). The incidences of FPG, 2HPG, TC, TG, LDL, FINS, PINS and diabetes in rosiglitazone group were significantly lower than those in placebo group, while HDL-C was increased. Conclusions Rosiglitazone can reduce the incidence of diabetes mellitus in people with impaired glucose tolerance (IGT), and can significantly improve the glucose tolerance abnormality while regulating blood fat and insulin resistance.